Citius Oncology, Inc. (CTOR) — Financial ratios
Profitability, liquidity, leverage, and valuation ratios for Citius Oncology, Inc., with annual and quarterly history.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Valuation | ||||
| P/E Ratio | -6.01x | -4.70x | -80.55x | -94.85x |
| P/B Ratio | 3.32x | 2.16x | 40.05x | 28.41x |
| P/S Ratio | 0.00x | 0.00x | 0.00x | 0.00x |
| Profitability | ||||
| Gross Margin | 0.0% | 0.0% | 0.0% | 0.0% |
| Operating Margin | 0.0% | 0.0% | 0.0% | 0.0% |
| Net Margin | 0.0% | 0.0% | 0.0% | 0.0% |
| EBITDA Margin | 0.0% | 0.0% | 0.0% | 0.0% |
| Liquidity | ||||
| Current Ratio | 0.56x | 0.34x | 0.37x | 0.46x |
| Quick Ratio | 0.11x | 0.08x | 0.37x | 0.46x |
| Leverage | ||||
| Debt/Equity | 0.08x | 0.08x | 0.00x | 0.00x |
YoY = year-over-year change. Source: FMP..